Anti-CD47 mAb (B6H12) exerts a synergistic effect in patient-derived xenograft (PDX) mice, suggesting this combined regimen as an interesting approach for HCC treatment [89]. This evidence concerns the gene CD47 and hepatocellular carcinoma.